Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 06 2020
15 06 2020
Historique:
received:
28
05
2019
revised:
01
11
2019
accepted:
03
01
2020
pubmed:
9
1
2020
medline:
14
9
2021
entrez:
9
1
2020
Statut:
ppublish
Résumé
Tumor genomic features have been of particular interest because of their potential impact on the tumor immune microenvironment and response to immunotherapy. Due to the substantial heterogeneity, an integrative approach incorporating diverse molecular features is needed to characterize immunologic features underlying primary resistance to immunotherapy and for the establishment of novel predictive biomarkers. We developed a pan-cancer deep machine learning model integrating tumor mutation burden, microsatellite instability, and somatic copy-number alterations to classify tumors of different types into different genomic clusters, and assessed the immune microenvironment in each genomic cluster and the association of each genomic cluster with response to immunotherapy. Our model grouped 8,646 tumors of 29 cancer types from The Cancer Genome Atlas into four genomic clusters. Analysis of RNA-sequencing data revealed distinct immune microenvironment in tumors of each genomic class. Furthermore, applying this model to tumors from two melanoma immunotherapy clinical cohorts demonstrated that patients with melanoma of different genomic classes achieved different benefit from immunotherapy. Interestingly, tumors in cluster 4 demonstrated a cold immune microenvironment and lack of benefit from immunotherapy despite high microsatellite instability burden. Our study provides a proof for principle that deep learning modeling may have the potential to discover intrinsic statistical cross-modality correlations of multifactorial input data to dissect the molecular mechanisms underlying primary resistance to immunotherapy, which likely involves multiple factors from both the tumor and host at different molecular levels.
Identifiants
pubmed: 31911545
pii: 1078-0432.CCR-19-1744
doi: 10.1158/1078-0432.CCR-19-1744
pmc: PMC7299824
mid: NIHMS1548760
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2908-2920Subventions
Organisme : NCI NIH HHS
ID : R21 CA227996
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Blood. 2017 Jul 27;130(4):453-459
pubmed: 28600341
IEEE/ACM Trans Comput Biol Bioinform. 2015 Jul-Aug;12(4):928-37
pubmed: 26357333
Science. 2017 Jan 20;355(6322):
pubmed: 28104840
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Nat Rev Genet. 2019 Jul;20(7):389-403
pubmed: 30971806
Science. 2006 Jul 28;313(5786):504-7
pubmed: 16873662
Science. 2015 Jan 9;347(6218):1254806
pubmed: 25525159
Br J Cancer. 2018 Jul;119(2):153-159
pubmed: 29955135
Cell Rep. 2017 Jan 3;18(1):248-262
pubmed: 28052254
Nat Genet. 2019 Jan;51(1):12-18
pubmed: 30478442
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
IEEE Trans Pattern Anal Mach Intell. 2013 Aug;35(8):1915-29
pubmed: 23787344
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Genome Biol. 2011;12(4):R41
pubmed: 21527027
Cell. 2018 Apr 5;173(2):371-385.e18
pubmed: 29625053
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Nature. 2015 May 28;521(7553):436-44
pubmed: 26017442
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Cancer Res. 2015 Sep 1;75(17):3446-55
pubmed: 26060019
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Cancer Res. 2017 Mar 15;77(6):1271-1282
pubmed: 28126714
Nature. 2017 Feb 2;542(7639):115-118
pubmed: 28117445
Cancer Immunol Res. 2016 Oct;4(10):820-822
pubmed: 27538576
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Nat Genet. 2013 Oct;45(10):1127-33
pubmed: 24071851
Lancet Oncol. 2016 Nov;17(11):1497-1508
pubmed: 27745820
Nat Methods. 2015 Oct;12(10):931-4
pubmed: 26301843
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Nature. 2013 Oct 17;502(7471):333-339
pubmed: 24132290
Genome Biol. 2016 Aug 22;17(1):174
pubmed: 27549193
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Nat Med. 2019 Jan;25(1):24-29
pubmed: 30617335
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Nat Commun. 2013;4:2612
pubmed: 24113773
Curr Opin Pharmacol. 2015 Aug;23:32-8
pubmed: 26047524
Bioinformatics. 2014 Apr 1;30(7):1015-6
pubmed: 24371154
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
Adv Immunol. 2016;130:75-93
pubmed: 26923000
Cell. 2016 Oct 6;167(2):397-404.e9
pubmed: 27667683
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349